Value Aggregated Treatment Data Life Science Companies Pharma Aptitude Health Blog

The Value That Aggregated Treatment Data Provides to Life Science Companies

The medical and pharmaceutical industries are dependent upon access to large amounts of patient data and utilizing this information in their research and the decisions they make regarding drug development and commercialization. Life science companies must continuously sift through mountains of clinical data. They are challenged with placing these data into their proper context to ensure they are utilized appropriately. With a never-ending flow of information, contextualizing data can be a Herculean task. Many organizations struggle to make sense of the heaps of information they are receiving on an ongoing basis from clinical trials, practicing physician feedback, and clinical advisors.

Curated insight reports from community physicians provide significant value to life science companies; these reports offer a unique window into the minds of healthcare providers. They explore treatment recommendations, provide feedback from clinician experience, and identify patient priorities. However, insight reports often vary in scope and quality.

Aptitude Health’s CASES reports identify key shifts in the healthcare marketplace related to the management of patients with hematologic malignancies and solid tumors. CASES reports help life science companies understand shifts in oncology care and identify education and resource needs. With CASES, you can track changes in clinical decision-making and shifts over time. Read on to learn more about the benefits of these insight reports.

How Can I Choose the Best Insight Reports?
There’s no doubt about it: life science companies offer a wealth of options when it comes to research reports . As you make your decision, look for insight reports that provide depth and breadth. The best insight reports provide a broad look at the current oncology landscape and are provided on an ongoing basis to measure changes over time. By analyzing treatment trends regularly and digging deep into different data points, a well-constructed report can determine the impact of emerging research and help life science companies better understand how they can support the clinical community.

A high-quality insight report offers a better understanding of the therapeutic decision-making process. This information helps guide ongoing clinical trials and drug developments. Remember to look for reports that use aggregated treatment data. This additional feature provides high levels of accuracy and is critical in specialties such as oncology. Consider the following benefits of insight reports that include aggerated data.

Aggregated Data Guide Clinical Decision-Making
Community physicians use the latest data to guide their treatment decisions; in turn, their treatment patterns impact the drug development process. The choices made by physicians help determine the fate of future treatments. As a result, physicians need to stay informed about emerging treatments and industry shifts. Life science companies also need to understand what goes on in the physician’s office.

Because of the global pandemic, outreach and marketing events have been paused. Insight reports help bridge the gap, allowing your company to understand current trends in treatment approaches. A well-constructed report can answer questions about physicians’ approaches and challenges and can provide additional feedback from clinical experts. Insight reports provide a widespread look at physician behavior and track changes over time. They reveal gaps in physicians’ understanding and conflicting priorities. Analyzing these data can positively impact your outreach efforts.

Aggregated Clinical Data Help Shape Drug Development
High-quality clinical data speed up drug development. With aggregated data from community practices, your organization can spot gaps in care within the current marketplace. You can assess whether available treatments have been used to their full potential. In some cases, insight reports may reveal that a new product is unlikely to gain traction or that additional education is needed to understand the value a newly approved therapy can provide . Paying attention to the details these reports can reveal may help your company avoid a failed product launch or proactively address an unmet need.

Keep in mind that aggregated clinical data go well beyond simple numbers. These reports do not just state how many doses of a specific drug were sold or how many patients were treated. Instead, they offer behind-the-scenes insights that can help your company make the smartest decisions possible. Aggregated clinical data found in insight reports place information in context, revealing nationwide and regional trends. These trends can have a significant impact on your company’s future.

Aggregated Data Reveal the Impact of Emerging Research
Insight reports track how clinician behavior shifts over time in regard to treatment approaches and utilization of particular therapeutics or diagnostic tests. Sometimes, you might notice immediately that prescribers’ behavior has not changed in response to new research. That may be a sign that community physicians have not received the educational support they need. Your organization can leverage this information by adjusting marketing and outreach efforts. Sharing relevant treatment data helps physicians provide patients with better care.

Your insight report might reveal other surprising information. For example, prescribers may shun an exciting new drug in favor of an old standby. These unexpected findings offer your company an opportunity to dig deeper. Insight reports point you in the right direction and using aggregated data allows you to better understand clinician priorities.

In-Depth Assessments of HCP Reactions to Data
If you’re looking for the right insight reports in oncology, Aptitude Health can help. Aptitude Health’s reports quickly identify and summarize oncology market dynamics tailored to your needs. They respond to rapid market shifts that impact clinical decision-making.

Each Aptitude Health report offers a rich source of real-world data whether it is focused on expert opinions or care in the community setting. Initial insights are collected from virtual or live roundtable discussions with clinicians who are focused on managing oncology patients with a particular malignancy. These roundtables, led by a key thought leader, may include 10–15 community physicians within the United States if the focus is care in outpatient setting. Discussions focus on specific disease states and analyze the current treatment landscape. Participants also discuss the ongoing impact of new clinical data.

Aptitude Health reports can provide insights into regionally distinct clinical patterns. They show how clinicians diagnose, treat, and respond to conditions within their geographic area. By aggregating many similar events, Aptitude Health provides a clear view of the changes in treatment patterns over time and in different regions.

Aptitude Health’s new service, RECAP, goes beyond a single CASES report. RECAP measures prescriber behavior, using the same set of community oncologists featured in CASES programs on a specific tumor type. RECAP assesses how prescribing habits have, or have not, changed over time within this group of clinicians. RECAP measures prescribing approaches, retention of program content, and challenges and barriers to adoption of therapies by community-based physicians in the US. Reports include a comprehensive data set, key takeaways with expert commentary, and strategic recommendations to help guide education and resource initiatives. RECAP reports allow your organization to zero in on community physicians in your region, providing an on-the-ground look at clinical decision-making and changes in care over time.